UCB SA (OTCMKTS:UCBJY) Sees Large Decline in Short Interest

UCB SA (OTCMKTS:UCBJY) was the recipient of a large decline in short interest during the month of April. As of April 30th, there was short interest totaling 201 shares, a decline of 82.7% from the April 15th total of 1,164 shares. Based on an average daily trading volume, of 107,071 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

UCB Price Performance

UCBJY traded up $1.76 during trading on Wednesday, reaching $139.55. 751 shares of the company’s stock were exchanged, compared to its average volume of 39,336. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38. The company’s fifty day simple moving average is $146.88 and its 200-day simple moving average is $145.24. UCB has a 1 year low of $84.94 and a 1 year high of $168.76.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on UCBJY shares. Zacks Research raised shares of UCB from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 14th. Wolfe Research upgraded UCB to a “strong-buy” rating in a research note on Monday, February 23rd. Three investment analysts have rated the stock with a Strong Buy rating, According to MarketBeat, UCB currently has a consensus rating of “Strong Buy”.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.